A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects

Clinical trial NCT02976857 · COMPLETED

Trial details

NCT number: NCT02976857
Sponsor: Shanghai AbelZeta Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Refractory Diffuse Large B-Cell Lymphoma

Start date: 2016-12-01
Primary completion: 2018-09-11
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.